Shopping Cart
Remove All
Your shopping cart is currently empty
ACY-1083 is a selective, brain-penetrating HDAC6 inhibitor (IC50: 3 nM) that effectively reverses chemotherapy-induced peripheral neuropathy.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $155 | In Stock | In Stock | |
| 5 mg | $328 | In Stock | In Stock | |
| 10 mg | $559 | In Stock | In Stock | |
| 25 mg | $883 | In Stock | In Stock | |
| 50 mg | $1,230 | In Stock | In Stock | |
| 100 mg | $1,660 | In Stock | In Stock | |
| 500 mg | $3,330 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $363 | In Stock | In Stock |
| Description | ACY-1083 is a selective, brain-penetrating HDAC6 inhibitor (IC50: 3 nM) that effectively reverses chemotherapy-induced peripheral neuropathy. |
| Targets&IC50 | HDAC1:17.2 μM, HDAC8:15.8 μM, HDAC2:70.7 μM, HDAC6:3 nM, HDAC4:12.5 μM, HDAC7:6.51 μM, HDAC5:4.17 μM, HDAC9:19.3 μM |
| In vitro | ACY-1083 (30 and 300 nM) dose-dependently improves cell viability[2]. |
| In vivo | In C57BL/6J mice, ACY-1083 (10 mg/kg; i.p.) effectively relieves Cisplatin-induced mechanical allodynia. In adult male SD rats, ACY-1083 (3 mg/kg; orally) reverses Paclitaxel-induced mechanical allodynia. ACY-1083(5 mg/kg; i.p.) shows a Cmax of 936 ng/mL, a half-life (T1/2) of 3.5h, and a biologically active plasma exposure of 8 hours[1]. |
| Molecular Weight | 348.35 |
| Formula | C17H18F2N4O2 |
| Cas No. | 1708113-43-2 |
| Smiles | ONC(=O)c1cnc(NC2(CCC(F)(F)CC2)c2ccccc2)nc1 |
| Relative Density. | 1.38 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 237.5 mg/mL (681.79 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (14.35 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.